NCT04560569 - Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

November 1, 2022

Study Completion Date

December 1, 2022

Conditions

HIV/AIDS

Interventions

DRUG

Albuvirtide

Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)

DRUG

3BNC117 Antibody

Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120

Trial Locations (7)

RECRUITING

ABT-3BNC117_203 Investigational Site, Decatur

RECRUITING

ABT-3BNC117_203 Investigational Site, Orlando

RECRUITING

ABT-3BNC117_203 Investigational Site, Hialeah

RECRUITING

ABT-3BNC117_203 Investigational Site, West Palm Beach

RECRUITING

ABT-3BNC117_203 Investigational Site, St Louis

RECRUITING

ABT-3BNC117_203 Investigational Site, Canoga Park

RECRUITING

ABT-3BNC117_203 Investigational Site, San Francisco